Cargando…
Management of Orthostatic Hypotension in Parkinson’s Disease
Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 mi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592655/ https://www.ncbi.nlm.nih.gov/pubmed/32716319 http://dx.doi.org/10.3233/JPD-202036 |
_version_ | 1783601229385957376 |
---|---|
author | Fanciulli, Alessandra Leys, Fabian Falup-Pecurariu, Cristian Thijs, Roland Wenning, Gregor K. |
author_facet | Fanciulli, Alessandra Leys, Fabian Falup-Pecurariu, Cristian Thijs, Roland Wenning, Gregor K. |
author_sort | Fanciulli, Alessandra |
collection | PubMed |
description | Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 minutes upon standing screen for OH at bedside. The medical history and cardiovascular autonomic function tests ultimately distinguish neurogenic OH, which is due to impaired sympathetic nerve activity, from non-neurogenic causes of OH, such as hypovolemia and BP lowering drugs. The correction of non-neurogenic causes and exacerbating factors, lifestyle changes and non-pharmacological measures are the cornerstone of OH treatment. If these measures fail, pharmacological interventions (sympathomimetic agents and/or fludrocortisone) should be introduced stepwise depending on the severity of symptoms. About 50% of patients with neurogenic OH also suffer from supine and nocturnal hypertension, which should be monitored for with in-office, home and 24 h-ambulatory BP measurements. Behavioral measures help prevent supine hypertension, which is eventually treated with non-pharmacological measures and bedtime administration of short-acting anti-hypertensive drugs in severe cases. If left untreated, OH impacts on activity of daily living and increases the risk of syncope and falls. Supine hypertension is asymptomatic, but often limits an effective treatment of OH, increases the risk of hypertensive emergencies and, combined with OH, facilitates end-organ damage. A timely management of both OH and supine hypertension ameliorates quality of life and prevents short and long-term complications in patients with Parkinson’s disease. |
format | Online Article Text |
id | pubmed-7592655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75926552020-10-30 Management of Orthostatic Hypotension in Parkinson’s Disease Fanciulli, Alessandra Leys, Fabian Falup-Pecurariu, Cristian Thijs, Roland Wenning, Gregor K. J Parkinsons Dis Review Orthostatic hypotension (OH) is a common non-motor feature of Parkinson’s disease that may cause unexplained falls, syncope, lightheadedness, cognitive impairment, dyspnea, fatigue, blurred vision, shoulder, neck, or low-back pain upon standing. Blood pressure (BP) measurements supine and after 3 minutes upon standing screen for OH at bedside. The medical history and cardiovascular autonomic function tests ultimately distinguish neurogenic OH, which is due to impaired sympathetic nerve activity, from non-neurogenic causes of OH, such as hypovolemia and BP lowering drugs. The correction of non-neurogenic causes and exacerbating factors, lifestyle changes and non-pharmacological measures are the cornerstone of OH treatment. If these measures fail, pharmacological interventions (sympathomimetic agents and/or fludrocortisone) should be introduced stepwise depending on the severity of symptoms. About 50% of patients with neurogenic OH also suffer from supine and nocturnal hypertension, which should be monitored for with in-office, home and 24 h-ambulatory BP measurements. Behavioral measures help prevent supine hypertension, which is eventually treated with non-pharmacological measures and bedtime administration of short-acting anti-hypertensive drugs in severe cases. If left untreated, OH impacts on activity of daily living and increases the risk of syncope and falls. Supine hypertension is asymptomatic, but often limits an effective treatment of OH, increases the risk of hypertensive emergencies and, combined with OH, facilitates end-organ damage. A timely management of both OH and supine hypertension ameliorates quality of life and prevents short and long-term complications in patients with Parkinson’s disease. IOS Press 2020-09-01 /pmc/articles/PMC7592655/ /pubmed/32716319 http://dx.doi.org/10.3233/JPD-202036 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Fanciulli, Alessandra Leys, Fabian Falup-Pecurariu, Cristian Thijs, Roland Wenning, Gregor K. Management of Orthostatic Hypotension in Parkinson’s Disease |
title | Management of Orthostatic Hypotension in Parkinson’s Disease |
title_full | Management of Orthostatic Hypotension in Parkinson’s Disease |
title_fullStr | Management of Orthostatic Hypotension in Parkinson’s Disease |
title_full_unstemmed | Management of Orthostatic Hypotension in Parkinson’s Disease |
title_short | Management of Orthostatic Hypotension in Parkinson’s Disease |
title_sort | management of orthostatic hypotension in parkinson’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592655/ https://www.ncbi.nlm.nih.gov/pubmed/32716319 http://dx.doi.org/10.3233/JPD-202036 |
work_keys_str_mv | AT fanciullialessandra managementoforthostatichypotensioninparkinsonsdisease AT leysfabian managementoforthostatichypotensioninparkinsonsdisease AT faluppecurariucristian managementoforthostatichypotensioninparkinsonsdisease AT thijsroland managementoforthostatichypotensioninparkinsonsdisease AT wenninggregork managementoforthostatichypotensioninparkinsonsdisease |